Information Provided By:
Fly News Breaks for November 7, 2019
AERI
Nov 7, 2019 | 09:03 EDT
Stifel analyst Annabel Samimy said Aerie Pharmaceuticals gave "another 'kitchen sinking' of guidance" due to uneven payer coverage of Rhopressa and Rocklatan. Aerie believes 2020 will be an important year to reach normalized payer coverage, but Samimy is resetting her estimates "to get out from under the weekly scrutiny" until investors "start looking beyond launch dynamics." She lowered her price target on Aerie to $45 to $77, but keeps a Buy rating as "shares are not even reflecting this draconian outlook or platform value."
News For AERI From the Last 2 Days
There are no results for your query AERI